alcoholic liver injury
Recently Published Documents


TOTAL DOCUMENTS

305
(FIVE YEARS 77)

H-INDEX

48
(FIVE YEARS 7)

2022 ◽  
Author(s):  
Cheng Fang ◽  
Qingwu Zhou ◽  
Qingyang Liu ◽  
Wei Jia ◽  
Yan Xu

This study demonstrates that compounds in baijiu, a traditional Chinese alcoholic beverage, can attenuate the development of ethanol-induced liver injury by regulating the crosstalk between gut microbiota and host lipid metabolism.


2021 ◽  
Vol 86 ◽  
pp. 104699
Author(s):  
Lingli Sun ◽  
Shuai Wen ◽  
Qiuhua Li ◽  
Xingfei Lai ◽  
Ruohong Chen ◽  
...  

Life Sciences ◽  
2021 ◽  
pp. 120180
Author(s):  
Hongwu Meng ◽  
Ruowen Niu ◽  
Hongmei You ◽  
Ling Wang ◽  
Rui Feng ◽  
...  

Phytomedicine ◽  
2021 ◽  
pp. 153845
Author(s):  
Lu Wang ◽  
Lina Kong ◽  
Shuai Xu ◽  
Xiaohui Wang ◽  
Kai Huang ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (20) ◽  
pp. 6301
Author(s):  
Jhao-Ru Lai ◽  
Ya-Wen Hsu ◽  
Tzu-Ming Pan ◽  
Chun-Lin Lee

Alcohol metabolism causes an excessive accumulation of liver lipids and inflammation, resulting in liver damage. The yellow pigments monascin (MS) and ankaflavin (AK) of Monascus purpureus-fermented rice were proven to regulate ethanol-induced damage in HepG2 cells, but the complete anti-inflammatory and anti-fatty liver mechanisms in the animal model are still unclear. This study explored the roles of MS and AK in improving alcoholic liver injury. MS and AK were simultaneously fed to evaluate their effects and mechanisms in C57BL/6J mice fed the Lieber–DeCarli liquid alcohol diet for 6 weeks. The results indicated that MS and AK significantly reduced the serum aspartate aminotransferase and alanine aminotransferase activity, as well as the total liver cholesterol and triglyceride levels. The histopathological results indicated that MS and AK prevented lipid accumulation in the liver. MS and AK effectively enhanced the activity of antioxidant enzymes and reduced the degree of lipid peroxidation; AK was particularly effective and exhibited a superior preventive effect against alcoholic liver injury and fatty liver. In addition to inhibiting the phosphorylation of the MAPK family, MS and AK directly reduced TNF-α, IL-6, and IL-1β levels, thereby reducing NF-κB and its downstream iNOS and COX-2 expressions, as well as increasing PPAR-γ, Nrf-2, and HO-1 expressions to prevent liver damage. MS and AK also directly reduced TNF-α, IL-6, and IL-1β expression, thereby reducing the production of NF-κB and its downstream iNOS and COX-2, and increasing PPAR-γ, Nrf-2, and HO-1 expressions, preventing alcohol damage to the liver.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yingting Zhang ◽  
Xidai Long ◽  
Xin Ruan ◽  
Qian Wei ◽  
Lin Zhang ◽  
...  

AbstractProtein acetylation has emerged to play pivotal roles in alcoholic liver disease (ALD). Sirutin 2 (SIRT2) is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase involved in the regulation of aging, metabolism, and stress. However, the role of SIRT2 in ALD remains unclear. Here, we report that the SIRT2-mediated deacetylation–deubiquitination switch of CCAAT/enhancer-binding protein beta (C/EBPβ) prevents ALD. Our results showed that hepatic SIRT2 protein expression was negatively correlated with the severity of alcoholic liver injury in ALD patients. Liver-specific SIRT2 deficiency sensitized mice to ALD, whereas transgenic SIRT2 overexpression in hepatocytes significantly prevented ethanol-induced liver injury via normalization of hepatic steatosis, lipid peroxidation, and hepatocyte apoptosis. Mechanistically, we identified C/EBPβ as a critical substrate of SIRT2 implicated in ALD. SIRT2-mediated deacetylation at lysines 102 and 211 decreased C/EBPβ ubiquitination, resulting in enhanced protein stability and subsequently increased transcription of C/EBPβ-target gene LCN2. Importantly, hepatic deacetylated C/EBPβ and LCN2 compensation reversed SIRT2 deletion-induced ALD aggravation in mice. Furthermore, C/EBPβ protein expression was positively correlated with SIRT2 and LCN2 expression in the livers of ALD patients and was inversely correlated with ALD development. Therefore, activating SIRT2-C/EBPβ-LCN2 signaling pathway is a potential therapy for ALD.


Sign in / Sign up

Export Citation Format

Share Document